A diverse collection of B cells responded to HIV infection in infant BG505.
Cale, Evan M
Shipley, Mackenzie M
MetadataShow full item record
Increasing evidence suggests infants develop unique neutralizing antibody (nAb) responses to HIV compared to adults. Here, we dissected the nAb response of an infant whose virus is in clinical trials as a vaccine immunogen, with a goal of characterizing the broad responses in the infant to this antigen. We isolated 73 nAbs from infant BG505 and identified a large number of clonal families. Twenty-six antibodies neutralized tier 2 viruses—in some cases, viruses from the same clade as BG505, and in others, a different clade, although none showed notable breadth. Several nAbs demonstrated antibody-dependent cellular cytotoxicity activity and targeted the V3 loop. These findings suggest an impressive polyclonal response to HIV infection in infant BG505, adding to the growing evidence that the nAb response to HIV in infants is polyclonal—a desirable vaccine response to a rapidly evolving virus like HIV.
CitationSimonich C, Shipley MM, Doepker L, et al. A diverse collection of B cells responded to HIV infection in infant BG505. Cell Rep Med. 2021;2(6):100314. Published 2021 Jun 15. doi:10.1016/j.xcrm.2021.100314.
University of Nairobi
RightsAttribution-NonCommercial-NoDerivs 3.0 United States
- Faculty of Health Sciences (FHS) 
The following license files are associated with this item: